• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    11/5/24 4:17:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELDN alert in real time by email
    SC 13G 1 tm2427451d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Eledon Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    28617K101

    (CUSIP Number)

     

     

    October 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RA Capital Management, L.P.  
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338 
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    IA, PN  

      

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Peter Kolchinsky
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    United States  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338  
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rajeev Shah
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    United States  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338  
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RA Capital Healthcare Fund, L.P.
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    PN

     

     

     

     

    Item 1(a).Name of Issuer:

     

    Eledon Pharmaceuticals, Inc. (the “Issuer”)

      

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    19800 MacArthur Blvd., Suite 250, Irvine, CA 92612

      

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

     

    Peter Kolchinsky

     

    Rajeev Shah

     

    RA Capital Healthcare Fund, L.P. (the “Fund”)

      

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships.

    Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    28617K101

      

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based upon the sum of (i) 39,655,702 shares of Common Stock outstanding as of August 14, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 19, 2024; and (ii) 18,356,173 shares of Common Stock issued in the Issuer’s public offering of equity securities that closed on October 30, 2024.

     

    The Fund directly holds 3,566,338 shares of Common Stock.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (“Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1:Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 5, 2024

      

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $ELDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELDN

    DatePrice TargetRatingAnalyst
    6/18/2025$9.00Buy
    H.C. Wainwright
    1/28/2025$9.00Buy
    Guggenheim
    5/13/2022$25.00 → $15.00Overweight
    Cantor Fitzgerald
    11/24/2021$35.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ELDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Eledon Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    6/18/25 7:57:38 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    1/28/25 7:12:35 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

    Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously

    5/13/22 9:03:12 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.

    SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    5/15/26 4:07:37 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.

    10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    5/13/26 4:20:36 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    5/13/26 4:15:17 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lee June converted options into 3,430 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:04 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcbride John S. converted options into 3,430 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:10 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Katkin Keith converted options into 8,575 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:06 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

    IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Gene

    6/4/26 4:31:28 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

    Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi

    5/27/26 7:55:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

    IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A

    5/20/26 4:05:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    5/13/24 5:04:15 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Leadership Updates

    Live Leadership Updates

    View All

    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

    Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera

    3/28/24 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  Dosed first participants in Phase 2 BESTOW trial in kidney transplantation  Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i

    1/4/24 4:40:44 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

    Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno

    11/9/23 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Financials

    Live finance-specific insights

    View All

    Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

    IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A

    5/20/26 4:05:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

    NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

    4/30/26 8:15:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

    Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²  Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Conference call to be held Friday, November 7 at 8:00 a.m. ET IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced results from it

    11/6/25 6:30:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/14/24 4:51:31 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 4:17:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 11:44:57 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care